Compound News and Research

RSS

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

New algorithm for faster human genome sequencing

In 2001, the Human Genome Project and Celera Genomics announced that after 10 years of work at a cost of some $400 million, they had completed a draft sequence of the human genome. Today, sequencing a human genome is something that a single researcher can do in a couple of weeks for less than $10,000.

11 Jul 2012

Read-through molecule improves muscle function in DMD

A compound that results in a read-through on nonsense mutations in messenger RNA restores dystrophin expression in an animal model of Duchenne muscular dystrophy, research shows.

9 Jul 2012

Researchers use metal complexes to modify peptide hormones

Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds.

9 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Genkyotex closes CHF25M Series C extension

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.

9 Jul 2012

Bayer commences enrollment in BAY94-9027 Phase II/III trial for hemophilia A

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A.

8 Jul 2012

Powerful new drug to treat malaria

A powerful new drug to treat malaria - the invention of a University of Nebraska Medical Center College of Pharmacy researcher -- will help take the bite out of malaria. In the United States, a mosquito bite seems harmless, but in developing countries it means more than 655,000 deaths a year - mostly in children.

7 Jul 2012

Reprogramming asthma-promoting immune cells diminishes airway damage and inflammation

Reprogramming asthma-promoting immune cells in mice diminishes airway damage and inflammation, and could potentially lead to new treatments for people with asthma, researchers have found.

5 Jul 2012

Intense war against malaria outlined by two studies in The American Journal of Tropical Medicine and Hygiene

A pair of provocative studies in the July 2012 issue of The American Journal of Tropical Medicine and Hygiene (AJTMH) provides a window into the intense ground war now underway against malaria.

4 Jul 2012

Physicists develop new nanoscale materials using moth eyes

Using the compound eyes of the humble moth as their inspiration, an international team of physicists has developed new nanoscale materials that could someday reduce the radiation dosages received by patients getting X-rayed, while improving the resolution of the resulting images.

4 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

GHB binds to GABAA-receptor in the brain under physiologically relevant conditions

Researchers are closer to understanding the biology behind GHB, a transmitter substance in the brain, best known in its synthetic form as the illegal drug fantasy. These findings have just been published in the scientific journal PNAS.

3 Jul 2012

Deleting a single gene results in autism-like behavior

Deleting a single gene in the cerebellum of mice can cause key autistic-like symptoms, researchers have found. They also discovered that rapamycin, a commonly used immunosuppressant drug, prevented these symptoms.

2 Jul 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

Powerful new technique can manipulate the building-block molecules of organic chemistry

Scientists at The Scripps Research Institute have developed a powerful new technique for manipulating the building-block molecules of organic chemistry. The technique enables chemists to add new functional molecules to previously hard-to-reach positions on existing compounds-making it easier for them to generate new drugs and other organic chemicals.

28 Jun 2012

New compound could treat certain types of genetic disorders in muscles

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

28 Jun 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012

DHA and curcumin help maintain neurological function after degenerative damage

UCLA researchers discovered that a diet enriched with a popular omega-3 fatty acid and an ingredient in curry spice preserved walking ability in rats with spinal-cord injury. Published June 26 in the Journal of Neurosurgery: Spine, the findings suggest that these dietary supplements help repair nerve cells and maintain neurological function after degenerative damage to the neck.

27 Jun 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

Compound News and Research

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

New algorithm for faster human genome sequencing

Read-through molecule improves muscle function in DMD

Researchers use metal complexes to modify peptide hormones

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

Genkyotex closes CHF25M Series C extension

Bayer commences enrollment in BAY94-9027 Phase II/III trial for hemophilia A

Powerful new drug to treat malaria

Reprogramming asthma-promoting immune cells diminishes airway damage and inflammation

Intense war against malaria outlined by two studies in The American Journal of Tropical Medicine and Hygiene

Physicists develop new nanoscale materials using moth eyes

Treating Sickle Cell Disease with L-Glutamine

GHB binds to GABAA-receptor in the brain under physiologically relevant conditions

Deleting a single gene results in autism-like behavior

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Powerful new technique can manipulate the building-block molecules of organic chemistry

New compound could treat certain types of genetic disorders in muscles

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

DHA and curcumin help maintain neurological function after degenerative damage

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News